Back Bay Sponsors 2019 Yale Innovation Summit EventsBack Bay Life Science AdvisorsMay 8, 2019Academia, Biotech, Commercialization, Life sciences seminar, Tech Transfer
Back Bay Provides Career Mentoring and Sponsorship to the Johns Hopkins Graduate Consulting Club Events, UncategorizedBack Bay Life Science AdvisorsApril 25, 2019Academia, Biotech, Life Science Career, mentoring
Boston Business Journal: The Fight over Local Talent NewsBack Bay Life Science AdvisorsApril 9, 2019Biotech, Boston Business Journal
Back Bay at BIO-Europe Spring, Vienna EventsInvestment Banking TeamMarch 25, 2019BIO Innovation, Biotech, Europe, Investment, Partnering
Back Bay on Bloomberg Baystate Business: Rare Disease Treatments News, UncategorizedBack Bay Life Science AdvisorsMarch 10, 2019BIO Innovation, Biotech, Drug development, Rare diseases
Xconomy: Gossamer Bio Turns Back from Alternative IPO Path News, Back Bay in the Newsjonathan gertlerFebruary 4, 2019Biotech, IPO
New White Paper: A Rare-Disease Approach to Seizure Treatment Michelle Hoffmann Posts, Susan Thompson Posts, WhitepapersBack Bay Life Science AdvisorsDecember 18, 2018Biotech, Drug development, Epilepsy, Rare diseases, Seizure
Asia Opens Its Doors for Pre-Revenue Biotechs Blog, Team PostsInvestment Banking TeamMay 29, 2018Biotech
Back Bay Celebrates 8 Years and 450 Life Science Assignments Blog, Jonathan Gertler Posts, Newsjonathan gertlerApril 2, 2018Biotech, cross-border, Denmark, healthcare, Jonathan Gertler, Wall Street Journal, WSJ
Danish Life Science Leaders and US Investors to Meet on Cross-Border Development Events, featured, NewsBack Bay Life Science AdvisorsMarch 28, 2018Biotech, DKBIO2018, Life sciences seminar
Xconomy: Proxima Aims to Fill CRO Gap for Houston’s Growing Biotech Community Jonathan Gertler Posts, News, Back Bay in the Newsjonathan gertlerMarch 14, 2018Biotech, healthcare, Jonathan Gertler, Wall Street Journal, WSJ
Life Science Leader: Dynamics and Value of Cross-Border Biotech Jonathan Gertler Posts, NewsBack Bay Life Science AdvisorsMarch 1, 2018Biotech, cross-border, Denmark, healthcare, Jonathan Gertler, Wall Street Journal, WSJ
STAT: Biosimilars, The Cure for Sky-High Drug Prices or a Stake in the Heart of Innovation? Michelle Hoffmann Posts, NewsBack Bay Life Science AdvisorsFebruary 9, 2018Biosimilars, Biotech, Michelle Hoffmann
Fierce CEO: Back Bay Life Science Advisors CEO Helps Healthcare Companies Grow featured, Jonathan Gertler Posts, NewsBack Bay Life Science AdvisorsJanuary 29, 2018Biotech, healthcare, Jonathan Gertler, Wall Street Journal, WSJ
White Paper: US Biosimilars 2018: Opportunities and Challenges News, WhitepapersBack Bay Life Science AdvisorsJanuary 3, 2018Biotech, healthcare, Jonathan Gertler, Wall Street Journal, WSJ
Wall Street Journal Pro Venture Capital: Back Bay’s Jonathan Gertler Comments on Biotech IPO Market Jonathan Gertler Posts, NewsBack Bay Life Science AdvisorsOctober 3, 2017Biotech, healthcare, Jonathan Gertler, Wall Street Journal, WSJ
Back Bay Life Science Advisors and Gorrissen Federspiel Life Sciences Seminar Events, NewsBack Bay Life Science AdvisorsSeptember 26, 2017Biotech, Life sciences seminar
Wall Street Journal: Rise of Earnouts Muddies M&A Waters Jonathan Gertler Posts, NewsBack Bay Life Science AdvisorsAugust 30, 2017Biotech, healthcare, Jonathan Gertler, Wall Street Journal, WSJ
Precision Medicine and the Age of Collaboration Blog, Jonathan Gertler Posts, NewsBack Bay Life Science AdvisorsAugust 7, 2017Biotech, healthcare, Jonathan Gertler, Precision medicine
Boston Business Journal: A Potential Inflection Point for Biogen Jonathan Gertler Posts, NewsBack Bay Life Science AdvisorsJuly 20, 2017Biotech, Boston Business Journal, IPO, Jonathan Gertler
